anivecrine   Click here for help

GtoPdb Ligand ID: 14661

Synonyms: octaaminoaccridine | octahydroaminoacridine
Approved drug
anivecrine is an approved drug
Compound class: Synthetic organic
Comment: Anivecrine is a acetylcholinesterase (AChE)/butyrylcholinesterase (BuChE) inhibitor. Chemically it is a tacrine analogue, that is modified to reduce liver toxicity [2]. Formulated as the succinate salt for clinical use.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 38.38
Molecular weight 202.3
XLogP 1.31
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCC2=NC3=C(CCCC3)C(=C2C1)N
Isomeric SMILES C1CCC2=C(C1)C(=C3CCCCC3=N2)N
InChI InChI=1S/C13H18N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1-8H2,(H2,14,15)
InChI Key BMRFESVZYWRROS-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Anivecrine was progressed as a clinical candidate for the treatment of Alzheimer's disease [2]. First approval for this indication was granted by China's NMPA in June 2026.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01569516 Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease Phase 2 Interventional Changchun Huayang High-tech Co., Ltd
NCT03283059 Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease Phase 3 Interventional Shanghai Mental Health Center